Literature DB >> 34739872

A multi-omic single-cell landscape of human gynecologic malignancies.

Matthew J Regner1, Kamila Wisniewska2, Susana Garcia-Recio2, Aatish Thennavan3, Raul Mendez-Giraldez2, Venkat S Malladi4, Gabrielle Hawkins5, Joel S Parker6, Charles M Perou7, Victoria L Bae-Jump8, Hector L Franco9.   

Abstract

Deconvolution of regulatory mechanisms that drive transcriptional programs in cancer cells is key to understanding tumor biology. Herein, we present matched transcriptome (scRNA-seq) and chromatin accessibility (scATAC-seq) profiles at single-cell resolution from human ovarian and endometrial tumors processed immediately following surgical resection. This dataset reveals the complex cellular heterogeneity of these tumors and enabled us to quantitatively link variation in chromatin accessibility to gene expression. We show that malignant cells acquire previously unannotated regulatory elements to drive hallmark cancer pathways. Moreover, malignant cells from within the same patients show substantial variation in chromatin accessibility linked to transcriptional output, highlighting the importance of intratumoral heterogeneity. Finally, we infer the malignant cell type-specific activity of transcription factors. By defining the regulatory logic of cancer cells, this work reveals an important reliance on oncogenic regulatory elements and highlights the ability of matched scRNA-seq/scATAC-seq to uncover clinically relevant mechanisms of tumorigenesis in gynecologic cancers.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chromatin accessibility; endometrial cancer; enhancer elements; gastro-intestinal stromal tumors; gene regulation; intratumoral heterogeneity; ovarian cancer; scATAC-seq; scRNA-seq; single-cell genomics

Mesh:

Substances:

Year:  2021        PMID: 34739872      PMCID: PMC8642316          DOI: 10.1016/j.molcel.2021.10.013

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  112 in total

1.  Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours.

Authors:  Dawn R Cochrane; Kieran R Campbell; Kendall Greening; Germain C Ho; James Hopkins; Minh Bui; J Maxwell Douglas; Vassilena Sharlandjieva; Aslı D Munzur; Daniel Lai; Maya DeGrood; Evan W Gibbard; Samuel Leung; Niki Boyd; Angela S Cheng; Christine Chow; Jamie Lp Lim; David A Farnell; Stefan Kommoss; Friedrich Kommoss; Andrew Roth; Lien Hoang; Jessica N McAlpine; Sohrab P Shah; David G Huntsman
Journal:  J Pathol       Date:  2020-08-22       Impact factor: 7.996

2.  FIMO: scanning for occurrences of a given motif.

Authors:  Charles E Grant; Timothy L Bailey; William Stafford Noble
Journal:  Bioinformatics       Date:  2011-02-16       Impact factor: 6.937

3.  Software for computing and annotating genomic ranges.

Authors:  Michael Lawrence; Wolfgang Huber; Hervé Pagès; Patrick Aboyoun; Marc Carlson; Robert Gentleman; Martin T Morgan; Vincent J Carey
Journal:  PLoS Comput Biol       Date:  2013-08-08       Impact factor: 4.475

4.  Value of HE4 Combined with Cancer Antigen 125 in the Diagnosis of Endometrial Cancer.

Authors:  Chunhua Dong; Ping Liu; Chao Li
Journal:  Pak J Med Sci       Date:  2017 Jul-Aug       Impact factor: 1.088

5.  Combinatorial perturbation analysis reveals divergent regulations of mesenchymal genes during epithelial-to-mesenchymal transition.

Authors:  Kazuhide Watanabe; Nicholas Panchy; Shuhei Noguchi; Harukazu Suzuki; Tian Hong
Journal:  NPJ Syst Biol Appl       Date:  2019-06-14

6.  The Transcription Factor Elf3 Is Essential for a Successful Mesenchymal to Epithelial Transition.

Authors:  Burcu Sengez; Ilkin Aygün; Huma Shehwana; Neslihan Toyran; Sanem Tercan Avci; Ozlen Konu; Marc P Stemmler; Hani Alotaibi
Journal:  Cells       Date:  2019-08-09       Impact factor: 6.600

7.  MEME SUITE: tools for motif discovery and searching.

Authors:  Timothy L Bailey; Mikael Boden; Fabian A Buske; Martin Frith; Charles E Grant; Luca Clementi; Jingyuan Ren; Wilfred W Li; William S Noble
Journal:  Nucleic Acids Res       Date:  2009-05-20       Impact factor: 16.971

8.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage.

Authors:  Dvir Aran; Agnieszka P Looney; Leqian Liu; Esther Wu; Valerie Fong; Austin Hsu; Suzanna Chak; Ram P Naikawadi; Paul J Wolters; Adam R Abate; Atul J Butte; Mallar Bhattacharya
Journal:  Nat Immunol       Date:  2019-01-14       Impact factor: 25.606

9.  A curated benchmark of enhancer-gene interactions for evaluating enhancer-target gene prediction methods.

Authors:  Jill E Moore; Henry E Pratt; Michael J Purcaro; Zhiping Weng
Journal:  Genome Biol       Date:  2020-01-22       Impact factor: 13.583

View more
  4 in total

1.  Single cell sequencing analysis and transcriptome analysis constructed the liquid-liquid phase separation(LLPS)-related prognostic model for endometrial cancer.

Authors:  Jiayang Wang; Fei Meng; Fei Mao
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

2.  Identification of a Gene Signature of Cancer-Associated Fibroblasts to Predict Prognosis in Ovarian Cancer.

Authors:  Li Zeng; Xuehai Wang; Fengxu Wang; Xinyuan Zhao; Yiqian Ding
Journal:  Front Genet       Date:  2022-07-06       Impact factor: 4.772

3.  A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer.

Authors:  Michael R Kelly; Kamila Wisniewska; Matthew J Regner; Michael W Lewis; Andrea A Perreault; Eric S Davis; Douglas H Phanstiel; Joel S Parker; Hector L Franco
Journal:  Nat Commun       Date:  2022-07-22       Impact factor: 17.694

4.  Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.

Authors:  Shruthi Sriramkumar; Tara X Metcalfe; Tim Lai; Xingyue Zong; Fang Fang; Heather M O'Hagan; Kenneth P Nephew
Journal:  PLoS One       Date:  2022-08-03       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.